Total Payments
$8,086
2024 Payments
$438.05
Companies
23
Transactions
191
Medicare Patients
1,828
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$4,121 (51.0%)
Food & Beverage$3,784 (46.8%)
Education$179.96 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Debt forgiveness | $4,121 | 1 | 51.0% |
| Food and Beverage | $3,784 | 184 | 46.8% |
| Education | $179.96 | 6 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neuronetics, Inc. | $4,503 | 11 | $0 (2023) |
| ABBVIE INC. | $937.47 | 53 | $0 (2024) |
| Allergan, Inc. | $538.49 | 37 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $402.06 | 20 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $352.66 | 16 | $0 (2022) |
| ITI, Inc. | $220.97 | 6 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $165.69 | 8 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $150.43 | 6 | $0 (2024) |
| Bausch Health US, LLC | $141.18 | 6 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $120.15 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $438.05 | 18 | Alkermes, Inc. ($90.33) |
| 2023 | $4,530 | 20 | Neuronetics, Inc. ($4,121) |
| 2022 | $320.45 | 18 | ABBVIE INC. ($169.86) |
| 2021 | $967.26 | 43 | AbbVie Inc. ($541.89) |
| 2020 | $241.93 | 15 | Allergan, Inc. ($158.74) |
| 2019 | $720.78 | 41 | Vanda Pharmaceuticals Inc. ($175.08) |
| 2018 | $448.04 | 16 | Neuronetics, Inc. ($162.15) |
| 2017 | $418.79 | 20 | Allergan Inc. ($184.67) |
All Payment Transactions
191 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $34.07 | General |
| Category: Neuroscience | ||||||
| 09/17/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $41.80 | General |
| Category: CNS | ||||||
| 08/12/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $32.12 | General |
| Category: Central Nervous System | ||||||
| 08/07/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: PSYCHIATRY | ||||||
| 07/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.39 | General |
| Category: NEUROSCIENCE | ||||||
| 06/25/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: PSYCHIATRY | ||||||
| 06/12/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.65 | General |
| Category: PSYCHIATRY | ||||||
| 05/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.37 | General |
| Category: NEUROSCIENCE | ||||||
| 04/16/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: PSYCHIATRY | ||||||
| 04/15/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: CNS | ||||||
| 03/27/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.27 | General |
| Category: NEUROSCIENCE | ||||||
| 03/19/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: ANTI-ANXIETY | ||||||
| 02/27/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: PSYCHIATRY | ||||||
| 02/23/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: CNS | ||||||
| 02/21/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: PSYCHIATRY | ||||||
| 02/08/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: CNS | ||||||
| 02/01/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $27.89 | General |
| Category: PSYCHIATRY | ||||||
| 01/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: NEUROSCIENCE | ||||||
| 11/28/2023 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: NEUROSCIENCE | ||||||
| 11/28/2023 | Bausch Health US, LLC | WELLBUTRIN (Drug), APLENZIN | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Neurology | ||||||
| 10/31/2023 | Neuronetics, Inc. | NEUROSTAR TMS THERAPY SYSTEM (Device) | Debt forgiveness | Cash or cash equivalent | $4,121.26 | General |
| Category: NEUROSTAR TMS THERAPY SYSTEM | ||||||
| 10/16/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: NEUROSCIENCE | ||||||
| 09/14/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: NEUROSCIENCE | ||||||
| 08/21/2023 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 438 | 3,994 | $699,708 | $397,907 |
| 2022 | 9 | 486 | 3,458 | $689,680 | $349,014 |
| 2021 | 8 | 478 | 2,936 | $607,829 | $277,213 |
| 2020 | 9 | 426 | 3,178 | $646,171 | $301,985 |
Total Patients
1,828
Total Services
13,566
Medicare Billing
$1.3M
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2023 | 28 | 829 | $331,600 | $135,474 | 40.9% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 133 | 1,475 | $144,759 | $106,021 | 73.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 79 | 766 | $112,360 | $82,687 | 73.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 120 | 778 | $82,882 | $56,983 | 68.8% |
| 90847 | Family psychotherapy with patient, 50 minutes | Office | 2023 | 22 | 81 | $9,683 | $6,545 | 67.6% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2023 | 15 | 16 | $8,000 | $4,526 | 56.6% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 23 | 24 | $7,791 | $3,758 | 48.2% |
| 90846 | Family psychotherapy without patient, 50 minutes | Office | 2023 | 18 | 25 | $2,633 | $1,913 | 72.6% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2022 | 32 | 888 | $355,300 | $146,971 | 41.4% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2022 | 143 | 1,188 | $135,100 | $85,468 | 63.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 69 | 513 | $67,769 | $49,774 | 73.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 136 | 714 | $81,655 | $43,606 | 53.4% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2022 | 26 | 26 | $13,000 | $7,438 | 57.2% |
| 90869 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent motor threshold redetermination with delivery and management | Office | 2022 | 11 | 25 | $12,500 | $5,968 | 47.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 26 | 27 | $8,600 | $3,695 | 43.0% |
| 90847 | Family psychotherapy with patient, 50 minutes | Office | 2022 | 22 | 47 | $11,023 | $3,655 | 33.2% |
| 90846 | Family psychotherapy without patient, 50 minutes | Office | 2022 | 21 | 30 | $4,732 | $2,440 | 51.6% |
| 90868 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), subsequent delivery and management, per session | Office | 2021 | 28 | 709 | $283,400 | $117,942 | 41.6% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2021 | 145 | 1,017 | $133,870 | $70,464 | 52.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 138 | 872 | $117,175 | $51,888 | 44.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 64 | 204 | $29,738 | $19,887 | 66.9% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 44 | 45 | $14,987 | $6,201 | 41.4% |
| 90867 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), initial delivery and management | Office | 2021 | 18 | 18 | $9,000 | $5,040 | 56.0% |
| 90847 | Family psychotherapy including patient, 50 minutes | Office | 2021 | 17 | 37 | $9,972 | $3,136 | 31.4% |
| 90846 | Family psychotherapy, 50 minutes | Office | 2021 | 24 | 34 | $9,687 | $2,654 | 27.4% |
About Dr. Alan Manevitz, M.D
Dr. Alan Manevitz, M.D is a Psychiatry healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1093860975.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Manevitz, M.D has received a total of $8,086 in payments from pharmaceutical and medical device companies, with $438.05 received in 2024. These payments were reported across 191 transactions from 23 companies. The most common payment nature is "Debt forgiveness" ($4,121).
As a Medicare-enrolled provider, Manevitz has provided services to 1,828 Medicare beneficiaries, totaling 13,566 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location New York, NY
- Active Since 01/24/2007
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1093860975
Products in Payments
- NEUROSTAR TMS THERAPY SYSTEM (Device) $4,146
- VRAYLAR (Drug) $1,341
- NEUROSTAR TMS THERAPY (Device) $317.10
- CAPLYTA (Drug) $300.91
- Hetlioz (Drug) $255.79
- Trintellix (Drug) $227.10
- REXULTI (Drug) $180.28
- SPRAVATO (Drug) $150.43
- TRINTELLIX (Drug) $146.96
- QELBREE (Drug) $115.34
- APLENZIN (Drug) $97.20
- NAMENDA XR (Drug) $95.37
- ABILIFY MAINTENA (Drug) $68.25
- Fanapt (Drug) $58.32
- ARISTADA (Drug) $48.53
- NUPLAZID (Drug) $45.56
- LATUDA (Drug) $44.72
- WELLBUTRIN (Drug) $43.98
- LYBALVI (Drug) $41.80
- NeuroStar TMS Therapy (Device) $39.49
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in New York
Dr. Manish Zinzuvadia, M.d, M.D
Psychiatry — Payments: $1.3M
Psychiatry $1.3M
Dr. Jianping Chen, M.d, M.D
Psychiatry — Payments: $1.1M
Psychiatry $1.1M
Dr. Ulla Laakso, Md, MD
Psychiatry — Payments: $957,236
Psychiatry $957,236
Dr. Kerry Sulkowicz, M.d, M.D
Psychiatry — Payments: $476,134
Psychiatry $476,134
Dr. Ralph Aquila, M.d, M.D
Psychiatry — Payments: $327,213
Psychiatry $327,213
Dr. Paul Eder, M.d, M.D
Psychiatry — Payments: $278,989
Psychiatry $278,989